Diabetes secondary to chronic pancreatitis and pancreatic cancer: Observations from the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)

IF 3.9 2区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Pancreatology Pub Date : 2026-06-01 Epub Date: 2026-04-03 DOI:10.1016/j.pan.2026.04.001

Phil A. Hart , Dana K. Andersen , Melena D. Bellin , Yogish C. Kudva , Frederico G.S. Toledo , Mark O. Goodarzi

{"title":"Diabetes secondary to chronic pancreatitis and pancreatic cancer: Observations from the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)","authors":"Phil A. Hart , Dana K. Andersen , Melena D. Bellin , Yogish C. Kudva , Frederico G.S. Toledo , Mark O. Goodarzi","doi":"10.1016/j.pan.2026.04.001","DOIUrl":null,"url":null,"abstract":"<div><div>Diabetes secondary to diseases of the exocrine pancreas, including chronic pancreatitis (CP) and pancreatic cancer (PDAC), is easily confused with type 2 diabetes (T2D). Misdiagnosis as T2D is common due to poor understanding of the underlying pathophysiology of these diabetes subtypes. In this review, we highlight contributions from our research group to further characterize the distinctions between CP-DM and PDAC-DM as it relates to postprandial response to pancreatic polypeptide (PP) and key metabolic alterations compared to T2D. In general, the PP response is blunted, and there is relatively lower insulin secretion, higher insulin sensitivity, and alpha cell dysregulation in CP-DM and PDAC when compared to T2D. Additionally, we provide updates regarding ongoing work to use clinical and genetic data to model the prediction of incident CP-DM. Lastly, we identify remaining knowledge gaps to further improve the diagnosis and treatment of type 3c diabetes.</div></div>","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":"26 4","pages":"Pages 581-586"},"PeriodicalIF":3.9000,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pancreatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1424390326001432","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Diabetes secondary to diseases of the exocrine pancreas, including chronic pancreatitis (CP) and pancreatic cancer (PDAC), is easily confused with type 2 diabetes (T2D). Misdiagnosis as T2D is common due to poor understanding of the underlying pathophysiology of these diabetes subtypes. In this review, we highlight contributions from our research group to further characterize the distinctions between CP-DM and PDAC-DM as it relates to postprandial response to pancreatic polypeptide (PP) and key metabolic alterations compared to T2D. In general, the PP response is blunted, and there is relatively lower insulin secretion, higher insulin sensitivity, and alpha cell dysregulation in CP-DM and PDAC when compared to T2D. Additionally, we provide updates regarding ongoing work to use clinical and genetic data to model the prediction of incident CP-DM. Lastly, we identify remaining knowledge gaps to further improve the diagnosis and treatment of type 3c diabetes.

查看原文本刊更多论文

继发于慢性胰腺炎和胰腺癌的糖尿病：来自慢性胰腺炎、糖尿病和胰腺癌研究联盟（CPDPC）的观察。

继发于外分泌胰腺疾病的糖尿病，包括慢性胰腺炎（CP）和胰腺癌（PDAC），很容易与2型糖尿病（T2D）混淆。由于对这些糖尿病亚型的潜在病理生理了解不足，误诊为T2D很常见。在这篇综述中，我们强调了我们的研究小组的贡献，以进一步表征CP-DM和PDAC-DM之间的区别，因为它与餐后对胰腺多肽（PP）的反应和与T2D相比的关键代谢改变有关。总的来说，与T2D相比，CP-DM和PDAC的PP反应减弱，胰岛素分泌相对较低，胰岛素敏感性较高，α细胞失调。此外，我们还提供了正在进行的使用临床和遗传数据建模预测CP-DM事件的最新工作。最后，我们确定了剩余的知识空白，以进一步改善3c型糖尿病的诊断和治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pancreatology 医学-胃肠肝病学

CiteScore

7.20

自引率

5.60%

发文量

194

审稿时长

44 days

期刊介绍： Pancreatology is the official journal of the International Association of Pancreatology (IAP), the European Pancreatic Club (EPC) and several national societies and study groups around the world. Dedicated to the understanding and treatment of exocrine as well as endocrine pancreatic disease, this multidisciplinary periodical publishes original basic, translational and clinical pancreatic research from a range of fields including gastroenterology, oncology, surgery, pharmacology, cellular and molecular biology as well as endocrinology, immunology and epidemiology. Readers can expect to gain new insights into pancreatic physiology and into the pathogenesis, diagnosis, therapeutic approaches and prognosis of pancreatic diseases. The journal features original articles, case reports, consensus guidelines and topical, cutting edge reviews, thus representing a source of valuable, novel information for clinical and basic researchers alike.